Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design

Journal of Medicinal Chemistry

Volumn 37, Issue 8, 1994, Pages 1035-1054

  Greer, Jonathan ^a,b,c,d   Erickson, John W ^a,b,c,d   Baldwin, John J ^a,b,c,d   Varney, Michael D ^a,b,c,d  

^a ABBOTT LABORATORIES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 74704; A 77003; A 78791; ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; ENZYME INHIBITOR; GAG PROTEIN; MVT 101; PROTEINASE; PROTEINASE INHIBITOR; RECEPTOR PROTEIN; SEZOLAMIDE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GLAUCOMA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE; PROTEIN PURIFICATION; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLIZATION; DRUG DESIGN; HIV PROTEASE INHIBITORS; HIV-1; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDYLATE SYNTHASE;

EID: 0028297112     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00034a001     Document Type: Article

References (116)

1. Propst, C. L.; Perun, T. J. Introduction to Computer-Aided Drug Design. In Computer-Aided Drug Design; Perun T. J., Propst, C. L., Eds.; Marcel Dekker, Inc.: New York, 1989; pp 1-18.
2. Black, J. Drugs from emasculated hormones: the principle of syntopic antagonism. Science 1989, 245, 486-493
3. Perun, T. J.; Propst, C. L. Computer-Aided Drug Design; Marcel Dekker, Inc.: New York, 1989; pp 493.
4. Martin, Y. C.; Danaher, E. B.; May, C. S.; Weininger, D.; Van Drie, J. H. Strategies in Drug Design Based on 3D-Structures of Ligands. In QSAR: Quantitative Structure-Activity Relationships in Drug Design; Alan R. Liss: New York, 1989; pp 177-181
5. Martin, Y. C. Overview of Concepts and Methods in Computer-Assisted Rational Drug Design. Methods Enzymol. 1991, 203, 587-613
6. Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; Dunn, D. A. The conformational parameter in drug design: the active analog approach. In Computer-Assisted Drug Design, American Chemical Society Symposium; Olson, E. C., Christofersen, R. E., Eds.; ACS: Washington, 1979; Vol. 112, pp 205-226
7. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 170, 5959-5967.
8. Abraham, D. J. X-Ray Crystallography and Drug Design. In Computer-Aided Drug Design; Perun, T. J., Propst, C. L., Eds.; Marcel Dekker, Inc.: New York, 1989; pp 93-132.
9. Fesik, S. W. Approaches to Drug Design Using Nuclear Magnetic Resonance Spectroscopy. In Computer-Aided Drug Design; Perun, T. J., Propst, C. L., Eds.; Marcel Dekker, Inc.: New York, 1989; pp 133-184.
10. Greer, J. Comparative model-building of the mammalian serine proteases. J. Mol. Biol. 1981, 153, 1027-1042.
11. Greer, J. Comparative Modeling Methods: Application to the Family of the Mammalian Serine Proteases. Proteins 1990, 7, 317-334.
12. Hutchins, C.; Greer, J. Comparative modeling of proteins in the design of novel renin inhibitors. Crit. Rev. Biochem. Mol. Biol. 1991, 26, 77-127.
13. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. J.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The protein data bank: a computer-based archival file for macromolecular structures. Arch. Biochem. Biophys. 1978, 185, 584-591
14. Bilofsky, H. S.; Burks, C.; Fickett, J. W.; Goad, W. B.; Lewitter, F. I.; Rindone, W. P.; Swindell, C. D.; Tung, C. S. The GenBank genetic sequence data bank. Nucleic Acid Res. 1986, 14, 1-4.
15. George, D. G.; Barker, W. C.; Hunt, L. T. The Protein Identification Resource (PIR). Nucleic Acids Res. 1986, 14, 11-16.
16. Hamm, G. H.; Cameron, G. N. The EMBL data library. Nucleic Acids Res. 1986, 14, 5-10
17. Mitsuya, H.; Yarchoan, R.; Broder, S. Molecular targets for AIDS therapy. Science 1990, 249, 1533-1544.
18. Debouck, C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 1992, 8, 153-164
19. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral inactivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
20. Kempf, D. J. Design of symmetry-based, peptidomimetic inhibitors of HIV protease. Methods Enzymol., in press.
21. Erickson, J.; Kempf, D. Structure-based design of symmetric inhibitors of HIV-1 protease. Arch. Virol., in press.
22. Erickson, J. W. Design and structure of symmetry-based inhibitors of HIV-1 protease. Perspect. Drug Dis. Design 1993, 1, 109-128.
23. Kempf, D. J.; Norbeck, D. W.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. F.; Wideburg, N. E.; Saldivar, A.; Craig-Kennard, A.; Vasavanonda, S.; Clement, J. J.; Erickson, J. Structure-based inhibitors of HIV protease. In Recent Advances in the Chemistry of Anti-infective Agents; Bentley, P. H., Ponsford, R., Eds.; Royal Society of Chemistry: Cambridge, 1993; pp 297-313
24. Wlodawer, A.; Erickson, J. W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 1993, 62, 543-585.
25. Appelt, K. Crystal structures of HIV-1 protease-inhibitor complexes. Perspect. Drug Dis. Design 1993, 1, 23-48.
26. Toh, H.; Ono, M.; Saigo, K.; Miyata, T. Retroviral protease-like sequence in the yeast transposon Tyl. Nature 1985, 315, 691-692.
27. Katoh, I.; Yasunaga, T.; Ikawa, Y.; Yoshinaka, Y. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor. Nature 1987, 329, 654-656.
28. Davies, D. R. The structure and function of the aspartic proteinases. Annu. Rev. Biophys. Biophys. Chem. 1990, 19, 189-215
29. Tang, J.; James, M. N. G.; Hsu, I. N.; Jenkins, J. A.; Blundell, T. L. Structural evidence for gene duplication in the evolution of the acid proteases. Nature 1978, 271, 618-621.
30. Miller, M.; Jaskolski, M.; Rao, J. K. M.; Leis, J.; Wlodawer, A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 1989, 337, 576-579.
31. Navia, M. A.; Fitzgerald, P. M. D.; McKeever, B. M.; Leu, C. T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989, 337, 615-620
32. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schneider, J.; Kent, S. B. M. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989, 245, 616-621
33. Lapatto, R.; Blundell, T.; Hennings, A.; Overington, J.; Wilderspin, A.; Wood, S.; Merson, J. R.; Whittle, P. J.; Danley, D. E.; Geoghegan, K. F.; Hawrylik, S. J.; Lee, S. E.; Scheld, K. G.; Hobart, P. M. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 1989, 342, 299-302.
34. Spinelli, S.; Liu, Q. Z.; Alzari, P. M.; Hirel, P. H.; Poljak, R. J. The three-dimensional structure of the aspartyl protease from the HI V-1 isolate BRU. Biochimie 1991, 73, 1391-1396
35. York, D. M.; Darden, T. A.; Pedersen, L. G.; Anderson, M. W. Molecular dynamics simulation of HIV-1 protease in a crystalline environment and in solution. Biochemistry 1993, 32, 1443-1453.
36. Rao, J. K. M.; Erickson, J. W.; Wlodawer, A. Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry 1991, 30, 4663-4671.
37. Greenlee, W. J. Renin inhibitors. Med. Res. Rev. 1990, 10, 173-236.
38. Meek, T. D. Inhibitors of HIV-1 protease. J. Enz. Inhib. 1992, 6, 65-98.
39. Huff, J. R. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
40. Norbeck, D. W.; Kempf, D. J. HIV protease inhibitors. Annu. Rep. Med. Chem. 1991, 26, 141-150.
41. Tomasselli, A. G.; Howe, W. J.; Sawyer, T. K.; Wlodawer, A.; Heinrikson, R. L. The complexities of AIDS: an assessment of the HIV protease as a therapeutic target. Chim. Oggi. 1991, 9, 6-27.
42. Plattner, J. J.; Norbeck, D. W. Obstacles to drug development from peptide leads. In Drug Discovery Technology, Clark, C. R., Moos, W. H., Eds.; Horwood: Chichester, UK, 1990; pp 92-126.
43. Erickson, J.; Neidhart, D. J.; VanDrie, J.; Kempf, D. J.; Wang, X. C.; Norbeck, D. W.; Plattner, J. J.; Rittenhouse, J. W.; Turon, M.; Wideburg, N.; Kohlbrenner, W. E.; Simmer, R.; Helfrich, R.; Paul, D. A.; Knigge, M. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990, 249, 527-533.
44. Kempf, D. J.; Norbeck, D. W.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Paul, D. A.; Knigge, M. F.; Vasavanonda, S.; Craig-Kennard, A.; Saldivar, A.; Rosenbrook, J. W.; Clement, J. J.; Plattner, J. J.; Erickson, J. Structure-based, C2 symmetric inhibitors of HIV protease. J. Med. Chem. 1990, 33, 2687-2689.
45. Rogers, E. F. The use and design of biligand enzyme inhibitors. J. Theor. Biol. 1984, 109, 471-474.
46. Beddell, C. R.; Goodford, P. J. Symmetry in prostaglandins. Prostaglandins 1977, 13, 494-502.
47. Pearl, L. H.; Taylor, W. R. A structural model for the retroviral proteases. Nature 1987, 329, 351-354
48. Suguna, K.; Padlan, E. A.; Smith, C. W.; Carlson, W. D.; Davies, D. R. Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7009-7013
49. Plattner, J. J.; Greer, J.; Fung, A. K.; Stein, H.; Kleinert, H. D.; Sham, H. L.; Smital, J. R.; Perun, T. J. Peptide analogues of angiotensinogen. Effect of peptide chain length on renin inhibition. Biochem. Biophys. Res. Commun. 1986, 139, 982-990
50. Matayoshi, E. D.; Wang, G. T.; Krafft, G. A.; Erickson, J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 1990, 247, 954-958.
51. Miller, M.; Schneider, J.; Sathyanarayana, B. K.; Toth, M. V.; Marshall, G. R.; Clawson, L.; Selk, L.; Kent, S. B. H.; Wlodawer, A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 1989, 246, 1149-1152.
52. Luly, J. R.; BaMaung, N.; Soderquist, J.; Fung, A. K. L.; Stein, H.; Kleinert, H. D.; Marcotte, P. A.; Egan, D.; Bopp, B.; Merits, I.; Bolis, G.; Greer, J.; Perun, T.; Plattner, J. J. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency. J. Med. Chem. 1988, 31, 2264-2276
53. Chenera, B.; Boehm, J. C.; Dreyer, G. B. Synthesis of C2-symmetric and pseudosymmetric HIV-1 protease inhibitors from D-mannitol and D-arabitol. Bioorg. Med. Chem. Lett. 1991, 4, 219-222.
54. Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; Marsh, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl- 3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J. Med. Chem. 1993, 36, 320-330.
55. Kempf, D. J.; Marsh, K.; Paul, D. A.; Knigge, M. F.; Norbeck, D. W.; Kohlbrenner, W. E.; Codacovi, L.; Vasavanonda, S.; Bryant, P.; Wang, X. C.; Wideburg, N. E.; Clement, J. J.; Plattner, J. J.; Erickson, J. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 1991, 35, 2209-2214
56. Hosur, M. V.; Bhat, T. N.; Kempf, D. J.; Baldwin, E. T.; Liu, B.; Gulnik, S.; Wideburg, N. E.; Norbeck, D. W.; Appelt, K.; Erickson, J. W. Influence of stereochemistry on activity and binding modes for C2 symmetry-based inhibitors of HIV-1 protease. J. Am. Chem. Soc., in press.
57. Dreyer, B. G.; Boehm, J. C.; Chenera, B.; DesJarlais, R. L.; Hassell, A. M.; Meek, T. D.; Tomaszek, T. A.; Lewis, M. A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry 1993, 32, 937-947
58. Norbeck, D.; Kempf, D.; Marsh, K.; Paul, D.; Knigge, M.; Vasavanonda, S.; Clement, J.; Kohlbrenner, W.; Sham, H.; Wideburg, N.; Plattner, J. Discovery of potent, orally bioavailable inhibitors of HIV protease. In Discovery of Potent, Orally Bioavailable Inhibitors of HIV Protease; VII International Conference on AIDS; Amsterdam, 1992; in press.
59. Abdel-Meguid, S. S.; Zhao, B.; Murthy, K. H. M.; Winborne, E.; Choi, J. K.; DesJarlais, R. L.; Minnich, M. D.; Culp, J. S.; Debouck, C.; Tomaszek, T. A.; Meek, T. D.; Dreyer, G. B. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis. Biochemistry 1993, 32, 7972-7980.
60. Johnson, V. A.; Merrill, D. P.; Chou, T. C.; Hirsch, M. S. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′- dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J. Infect. Dis. 1992, 166, 1143-1146
61. Lam, P. Y.-S.; Eyermann, C. J.; Hodge, C. N.; Jadhav, P. K.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, N. Y.; Chang, C. H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. De novo design and discovery of potent nonpeptide HIV protease inhibitors. Presented at the 205th American Chemical Society National Meeting; Denver, CO, 1993; No. 96.
62. Maren, T. H. Carbonic anhydrase—general perspectives and advances in glaucoma research. Drug. Dev. Res. 1987, 10, 255-276
63. Maren, T. H. The links among biochemistry, physiology, and pharmacology in carbonic anhydrase mediated systems. In Carbonic Anhydrase From Biochemistry and Genetics to Physiology and Clinical Medicine, International Workshop on Carbonic Anhydrase; Botre, F., Gros, G., Storey, B. T., Eds.; VCH Publishers: New York, 1991; pp 186-207.
64. Maren, T. H. Direct measurements of the rate constants of sulfonamides with carbonic anhydrase. Mol. Pharm. 1992, 41, 419-426.
65. Eriksson, A. E.; Jones, T. A.; Liljas, A. Crystallographic studies of human carbonic anhydrase II. In Progress in Inorganic Biochemistry and Biophysics, Zinc Emymes; Bertini, I., Luchinat, C., Maret, W., Zeppezauer, M., Eds.; Birkhauser Boston, Inc.: New York, 1986; Vol. 1, pp 317-328
66. Eriksson, A. E.; Jones, T. A.; Liljas, A. Refined structure of human carbonic anhydrase II at 2.0 Å resolution. Proteins 1988, 4, 274-282
67. Coleman, J. E. Chemical reactions of sulfonamides with carbonic anhydrase. Annu. Rev. Pharmacol. 1975, 15, 221-242.
68. Lindskog, S. The structural basis of kinetic differences between carbonic anhydrase isoenzymes. In Progress in Inorganic Biochemistry and Biophysics, Zinc Emymes; Bertini, I., Luchinat, C., Maret, W., Zeppezauer, M., Eds.; Birkhauser Boston, Inc.: New York, 1986; Vol. 1, pp 307-316.
69. Silverman, D. N.; Lindskog, S. The catalytic mechanism of carbonic anhydrase: implications of a rate-limiting protolysis of water. Acc. Chem. Res. 1988, 21, 30-36
70. Christianson, D. W. Structural biology of zinc. Adv. Prot. Chem. 1991, 42, 281-355.
71. Baldwin J. J.; Ponticello, G. S.; Anderson, P. S.; Christy, M. E.; Murcko, M. A.; Randall, W. C.; Schwam, H.; Sugrue, M. F.; Springer, J. P.; Gautheron, P.; Grove, J.; Mallorga, P.; Viader, M.-P.; McKeever, B. M.; Navia, M. A. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J. Med. Chem. 1989, 32, 2510-2513.
72. Sola, M.; Lledos, A.; Duran, M.; Bertran J. Anion binding and pentacoordination in zinc(II) complexes. Inorg. Chem. 1991, 30, 2523-2527
73. Alexander, R. S.; Nair, S. K.; Christianson, D. W. Engineering the hydrophobic pocket of carbonic anhydrase II. Biochemistry 1991, 30, 11064-11072.
74. Fierke, C. A.; Calderone, T. L.; Krebs, J. F. Functional consequences of engineering the hydrophobic pocket of carbonic anhydrase II. Biochemistry 1991, 30, 11054-11063.
75. Nair, S. K.; Calderone, T. L.; Christianson, D. W.; Fierke, C. A. Altering the mouth of a hydrophobic pocket. Structure and kinetics of human carbonic anhydrase II mutants at residue Val-121. J. Biol. Chem. 1991, 266, 17320-17325.
76. Krebs, J. F.; Fierke, C. A.; Alexander, R. S.; Christianson, D. W. Conformational mobility of His-64 in the Thr-200 ⟶ Ser mutant of human carbonic anhydrase II. Biochemistry 1991, 30, 9153-9160.
77. Jewell, D. A.; Tu, C.; Paranawithana, S. R.; Tanhauser, S. M.; LoGrasso, P. V.; Laipis, P. J.; Silverman, D. N. Enhancement of the catalytic properties of human carbonic anhydrase II by sitedirected mutagenesis. Biochemistry 1991, 30, 1484-1490.
78. Behravan, G.; Jonsson, B.-H.; Lindskog, S. Fine tuning of the catalytic properties of carbonic anhydrase. Studies of a Thr200 ⟶ His variant of human isoenzyme II. Eur. J. Biochem. 1990, 190, 351-357.
79. Vallee, B. L.; Auld, D. S. Active-site zinc ligands and activated H2O of zinc enzymes. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 220-224
80. Liang, J.-Y.; Lipscomb, W. N. Binding of substrate CO2 to the active site of human carbonic anhydrase II: a molecular dynamics study. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 3675-3679.
81. Liang, J.-Y.; Lipscomb, W. N. Application of quantum mechanical calculations to studies of enzymatic catalysis and inhibitor binding of human carbonic anhydrase II. In Structure and Methods, DNA Protein Complexes and Proteins, Proceedings of the Sixth Conversation in the Discipline Biomolecular Stereodynamics; Sarma, R. H., Sarma, M. H., Eds.; Adenine Press: Schenectady, 1990; Vol. 2, pp 181-194.
82. Tu, C.; Silverman, D. N.; Forsman, C.; Jonsson, B.-H.; Lindskog, S. Role of histidine 64 in the catalytic mechanism of human carbonic anhydrase II studied with a site-specific mutant. Biochemistry 1989, 28, 7913-7918.
83. Tu, C.; Paranawithana, S. R.; Jewell, D. A.; Tanhauser, S. M.; LoGrasso, P. V.; Wynns, G. C.; Laipis, P. J.; Silverman, D. N. Buffer enhancement of proton transfer in catalysis by human carbonic anhydrase II. Biochemistry 1990, 29, 6400-6405.
84. Coleman, J. E. Current concepts of the mechanism of action of carbonic anhydrase. In Proceedings in Life Sciences: Biophysics and Physiology of Carbon Dioxide; Bauer, C., Gros, G., Bartels, H., Eds.; Springer-Verlag: New York, 1980; pp 133-150.
85. Appelt, K.; Bacquet, R. J.; Bartlett, C. A.; Boothe, C. L. J.; Freer, S. T.; Fuhry, M. M.; Gehring, M. R.; Hermann, S. M.; Howland, E. F.; Janson, C. A.; Jones, T. R.; Kan, C.; Kathardekar, V.; Lewis, K. K.; Marzoni, G. P.; Matthews, D. A.; Mohr, C.; Moomaw, E. W.; Morse, C. A.; Oatley, S. J.; Ogden, R. C.; Reddy, M. R.; Reich, S. H.; Schoettlin, W. S.; Smith, W. W.; Varney, M. D.; Villafranca, J. E.; Ward, R. W.; Webber, S.; Webber, S. E.; Welsh, K. M.; White, J. Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis. J. Med. Chem. 1991, 34, 1925-1934
86. Varney, M. D.; Marzoni, G. P.; Palmer, C. L.; Deal, J. G.; Webber, S.; Welsh, K. M.; Bacquet, R. J.; Bartlett, C. A.; Morse, C. A.; Booth, C. L. J.; Hermann, S. M.; Howland, E. F.; Ward, R. W.; White, J. Crystal-Structure-Based Design and Synthesis of Benz-[cd] indole-Containing Inhibitors of Thymidylate Synthase. J. Med. Chem. 1992, 35, 663-676
87. Goodford, P. J. A computational procedure for determining energetically favourable binding sites on biologically important molecules. J. Med. Chem. 1985, 28, 849-857.
88. Bartlett, P. A.; Shea, G. T.; Telfer, S. J.; Waterman, S. CAVEAT: a program to facilitate the structure-derived design of biologically active molecules. Spec. Pub. R. Soc. Chem. 1989, 78, 182-196
89. Bohm, H.-J. LUDI: Rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput.-Aided Mol. Des. 1992, 6, 593-606
90. DesJarlais, R. L.; Sheridan, R. P.; Seibel, G. L.; Dixon, J. S.; Kuntz, I. D.; Venkataraghavan, R. Using Shape Complementarity as an Initial Screen in Designing Ligands for a Receptor Binding Site of Known Three-Dimensional Structure. J. Med. Chem. 1988, 31, 722-729.
91. VanDrie, J. H.; Weininger, D.; Martin, Y. C. ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures. J. Comput.-Aided Mol. Des. 1989, 3, 225-251
92. Freire, E. Structural Thermodynamics: Prediction of Protein Stability and Protein Binding Affinities. Arch. Biochem. Biophys. 1993, 303, 181-184
93. Lee, F. S.; Chu, Z. T.; Bolger, M. B. Calculations of antibodyantigen interactions: microscopic and semi-microscopic evaluation of the free energies of binding of phosphorylcholine analogs to McPC603. Protein Eng. 1992, 5, 215-228.
94. Lybrand, T. P.; McCammon, J. A.; Wipff, G. Theoretical calculation of relative binding affinity in host-guest systems. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 833-835.
95. Miyamoto, S.; Kollman, P. A. Absolute and relative binding free energy calculations of the interaction of biotin and its analogs with streptavidin using molecular dynamics/free energy perturbation approaches. Protein 1993, 16, 226-245
96. Murphy, K. P.; Xie, D.; Garcia, K. C.; Amzel, L. M.; Freire, E. Structural Energetics of Peptide Recognition: Angiotensin II/Antibody Binding. Protein 1993, 15, 113-120.
97. Novotny, J. Protein Antigenicity: A thermodynamic approach. Mol. Immunol. 1991, 28, 201-207.
98. Reddy, M. R.; Bacquet, R. J.; Zichi, D.; Matthews, D. A.; Weish, K. M.; Jones, T. R.; Freer, S. Calculation of solvation and binding free energy differences for folate-based inhibitors of the enzyme thymidylate synthase. J. Am. Chem. Soc. 1992, 114, 10117-10122
99. Williams, D. H.; Searle, M. S.; Mackay, J. P.; Gerhard, U.; Maplestone, R. A. Toward an estimation of binding constants in aqueous solution: Studies of associations of vascomycin group antibiotics. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1172-1178.
100. Richards, F. M. The protein folding problem. Sci. Am. 1991, 264 (1), 54-63
101. Creighton, T. E. The protein folding problem. Science 1988, 240, 267, 344.
102. Ring, C.S.; Cohen, F.E. Modeling protein structures: construction and their applications. FASEB J. 1993, 7, 783-790.
103. Yue, K.; Dill, K. A. Inverse protein folding problem: designing polymer sequences. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4163-4167.
104. Sander, C. Inverting the protein-folding problem. Biochem. Soc. Symp. 1990, 57, 25-33.
105. Bruccoleri, R. E.; Karplus, M. Conformational sampling using high temperature molecular dynamics. Biopolymers 1990, 29, 1847-1862.
106. Higo, J.; Collura, V.; Garnier, J. Development of an extended simulated annealing method: application to the modeling of complementary determining regions of immunoglobulins. Biopolymers 1992, 32, 33-43.
107. Martin, A. C.; Cheetham, J. C.; Rees, A. R. Modeling antibody hypervariable loops: a combined algorithm. Proc. Natl. Acad. Sci. U.S.A. 1989, 26, 9268-9272.
108. Thornton, J. M. Modelling antibody combining sites: a review. Ciba Found. Symp. 1991, 159, 55-69.
109. Bruccoleri, R. E.; Karplus, M. Prediction of the folding of short polypeptide segments by uniform conformational sampling. Biopolymers 1987, 26, 137-168.
110. Fine, R. M.; Wang, H.; Shenkin, P. S.; Yarmush, D. L.; Levinthal, C. Predicting antibody hypervariable loop conformations. II. Minimization and molecular dynamics studies of MCPC603 from many randomly generated loop conformations. Proteins 1986, 1, 342-362.
111. Moult, J.; James, M. N. G. An algorithm for determining the conformation of polypeptide segments in proteins by systematic search. Proteins 1986, 1, 146-163.
112. Shenkin, P. S.; Yarmush, D. L.; Fine, R. M.; Wang, H.; Levinthal, C. Predicting antibody hypervariable loop conformation. I. Ensembles of random conformations for ringlike structures. Biopolymers 1987, 26, 2053-2085.
113. Head, G. T.; Stillinger, F. H.; Arrecis, J. A strategy for finding classes of minima on a hypersurface: implications for approaches to the protein folding problem. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11076-11080.
114. Rabow, A. A.; Scheraga, H. A. Lattice neural network minimization. Application of neural network optimization for locating the global minimum conformations of proteins. J. Mol. Biol. 1993, 232, 1157-1168.
115. Ripoll, D. R.; Scheraga, H. A. The multiple-minima problem in the conformational analysis of polypeptides. III. An electrostatically driven Monte Carlo method: tests on enkephalin. J. Protein Chem. 1989, 8, 263-287.
116. Ripoll, D. R.; Piela, L.; Vasquez, M.; Scheraga, H. A. On the multipleminima problem in the conformational analysis of polypeptides. V. Application of the self-consistent electrostatic field and the electrostatically driven Monte Carlo methods to bovine pancreatic trypsin inhibitor. Proteins 1991, 10, 188-198